1. A therapeutic composition for treating and alleviating diseases and disorders related to cancer, comprising: a carrier selected from the group consisting of a non-cationic polymer carrier, a liposome carrier, a dendritic carrier, a nanomaterial carrier, a biostructure carrier and a micellar carrier； a targeting agent, operably linked to a carrier, wherein said targeting agent comprises a retinoid； an iterative agent operably linked to a carrier, wherein said therapeutic agent exhibits therapeutic activity upon delivery to a target organ or target tissue； wherein said therapeutic activity is an inhibition of cancer cell growth in said target organ or target tissue. The therapeutic composition according to claim 1, characterized in that the retinoid is selected from the group comprising retinol, retinal and retinoic acid. The therapeutic composition according to claim 1, wherein the retinoid is selected from the group consisting of fully trans retinol, completely trans retinoic acid, retinyl palmitate, 11-cis-retinal and 13-cis-retinoic acid. The therapeutic composition according to claim 1, characterized in that the target organ is selected from the group comprising the liver, pancreas, kidney, lung, esophagus, larynx, bone marrow, and brain. The therapeutic composition according to claim 1, characterized in that the targeting agent increases the selectivity of delivering the therapeutic composition after delivery to the target organ or target tissue by at least about two times compared with the increase caused by a comparable in other respects1. Терапевтическая композиция для лечения и облегчения заболеваний и расстройств, относящихся к раковым заболеваниям, содержащая:носитель, выбранный из группы, включающей некатионный полимерный носитель, липосомный носитель, дендритный носитель, носитель на основе наноматериала, биоструктурный носитель и мицеллярный носитель；нацеливающий агент, функционально связанный с носителем, при этом указанный нацеливающий агент содерж
